Company / Capital Returned to Shareholders per Share
Lilly (Eli) Capital Returned to Shareholders per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders per Share
$10.51
FY2025
5-year range
$3.49 / $10.51
FY2021-FY2025
Trend
+32.4%
vs FY2024
Sector context
#3 of 51
Health Care
What the data says
Among 51 Health Care companies, Lilly (Eli) is in the top 6% for capital returned to shareholders per share. Capital Returned to Shareholders per Share has increased for 3 consecutive years, from $3.49 in FY2022 to $10.51 in FY2025.
Based on SEC 10-K filings.
10.51 in FY2025 with a 5-year CAGR of +10.9%. Ranks 3rd among 51 companies in Health Care.
Improved from $4.76 to $10.51 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders per Share over time
Growth rates
- 3-Year CAGR
- +44.4%
- 5-Year CAGR
- +10.9%
- 10-Year CAGR
- -
Sector benchmark
+284.2% above sector average
Key checks
Key Insights
- Lilly (Eli)'s capital returned to shareholders per share has grown for 3 consecutive years.
- In FY2025, capital returned to shareholders per share increased 32.4% year-over-year.
- Ranks #3 out of 51 companies in the Health Care sector.
- Lowest capital returned to shareholders per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to Shareholders per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.51 | +32.4% |
| FY2024 | $7.94 | +66.9% |
| FY2023 | $4.76 | +36.2% |
| FY2022 | $3.49 | -52.0% |
| FY2021 | $7.28 | +16.4% |
| FY2020 | $6.25 | -3.4% |
| FY2019 | $6.47 | +6.4% |
| FY2018 | $6.09 | +125.5% |
| FY2017 | $2.70 | +5.1% |
| FY2016 | $2.57 | -3.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026